Journal Article

Treatment with Piperacillin-Tazobactam and False-Positive <i>Aspergillus</i> Galactomannan Antigen Test Results for Patients with Hematological Malignancies

Olivier Adam, Anne Aupérin, Fanny Wilquin, Jean-Henri Bourhis, Bertrand Gachot and Elisabeth Chachaty

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 6, pages 917-920
Published in print March 2004 | ISSN: 1058-4838
Published online March 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/383148
Treatment with Piperacillin-Tazobactam and False-Positive Aspergillus Galactomannan Antigen Test Results for Patients with Hematological Malignancies

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We report the occurrence of a high rate of false-positive test results during the surveillance of hematology patients for galactomannan (GM) antigenemia. Among 218 patients surveyed from June 2002 through June 2003, 42 (19.3%) had ⩾1 serum sample positive for GM (optical density index, >1.5). Of these patients, 38 had no additional evidence of invasive aspergillosis, and, therefore, their test results were considered to be false-positives. Case-control analysis showed that treatment with piperacillin-tazobactam was the only risk factor significantly associated with receiving false-positive test results. When tested for GM antigen, 3 of 4 piperacillin-tazobactam batches had positive results. Physicians should be aware of the possible interference of treatment with piperacillin-tazobactam when interpreting the results of the GM assay.

Journal Article.  2200 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.